China’s National Medical Products Administration approved the use of the Xen gel stent for the surgical management of patients with refractory glaucoma, according to an Allergan press release.
The National Medical Products Administration and Hainan Provincial Government created a real-world evidence pilot program in June 2019. When combined with data from controlled clinical trials, the real-world data enabled the assessment of ethnic differences to treatment with Xen, which helped to support the approval of the gel stent.
“We are honored that Xen has become the first medical
Uncategorized